Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Kennedy

Showing results (1061-1070 of 1,151) with videos related to

Pageof 116
Sort By:
Oncotarget|April 19, 2014
TBX2 represses CST6 resulting in uncontrolled legumain activity to sustain breast cancer proliferation: a novel cancer-selective target pathway with therapeutic opportunitiesZenobia C D'Costa, Catherine Higgins, Chee Wee Ong, et al.
Gynecologic Oncology|September 9, 2019
Defining the molecular evolution of extrauterine high grade serous carcinomaJames P Beirne, Darragh G McArt, Aideen Roddy, et al.
Diseases of the Colon and Rectum|January 6, 2022
Anal Adenocarcinoma: A Rare Entity in Need of Multidisciplinary ManagementJelena Lukovic, J John Kim, Zhihui Amy Liu, et al.
Pain|November 29, 2016
Peripheral neuropathic pain: a mechanism-related organizing principle based on sensory profilesRalf Baron, Christoph Maier, Nadine Attal, et al.
Analytical Chemistry|April 22, 2011
Quantitative measurement of JWH-018 and JWH-073 metabolites excreted in human urineCindy L Moran, Vi-Huyen Le, Krishna C Chimalakonda, et al.
ESMO Open|May 14, 2024
An investigation of the clinical impact and therapeutic relevance of a DNA damage immune response (DDIR) signature in patients with advanced gastroesophageal adenocarcinomaM A Baxter, L C Spender, D Cairns, et al.
British Journal of Cancer|November 3, 2021
Activation of a cGAS-STING-mediated immune response predicts response to neoadjuvant chemotherapy in early breast cancerEileen E Parkes, Kienan I Savage, Tong Lioe, et al.
The Journal of Infectious Diseases|July 19, 2021
Real-World Clinical Outcomes of Bamlanivimab and Casirivimab-Imdevimab Among High-Risk Patients With Mild to Moderate Coronavirus Disease 2019Ravindra Ganesh, Lindsey M Philpot, Dennis M Bierle, et al.
Nature Medicine|January 3, 2025
Sustained virologic suppression of multidrug-resistant HIV in an individual treated with anti-CD4 domain 1 antibody and lenacapavirM Ali Rai, Jana Blazkova, Lela Kardava, et al.
Oncotarget|May 3, 2018
Glucose transporter 1 expression as a marker of prognosis in oesophageal adenocarcinomaJaine K Blayney, Lauren Cairns, Gerald Li, et al.
Pageof 116

Showing results (1061-1070 of 1,151) with videos related to

Sort By:
Pageof 116
Oncotarget|April 19, 2014
TBX2 represses CST6 resulting in uncontrolled legumain activity to sustain breast cancer proliferation: a novel cancer-selective target pathway with therapeutic opportunitiesZenobia C D'Costa, Catherine Higgins, Chee Wee Ong, et al.
Gynecologic Oncology|September 9, 2019
Defining the molecular evolution of extrauterine high grade serous carcinomaJames P Beirne, Darragh G McArt, Aideen Roddy, et al.
Diseases of the Colon and Rectum|January 6, 2022
Anal Adenocarcinoma: A Rare Entity in Need of Multidisciplinary ManagementJelena Lukovic, J John Kim, Zhihui Amy Liu, et al.
Pain|November 29, 2016
Peripheral neuropathic pain: a mechanism-related organizing principle based on sensory profilesRalf Baron, Christoph Maier, Nadine Attal, et al.
Analytical Chemistry|April 22, 2011
Quantitative measurement of JWH-018 and JWH-073 metabolites excreted in human urineCindy L Moran, Vi-Huyen Le, Krishna C Chimalakonda, et al.
ESMO Open|May 14, 2024
An investigation of the clinical impact and therapeutic relevance of a DNA damage immune response (DDIR) signature in patients with advanced gastroesophageal adenocarcinomaM A Baxter, L C Spender, D Cairns, et al.
British Journal of Cancer|November 3, 2021
Activation of a cGAS-STING-mediated immune response predicts response to neoadjuvant chemotherapy in early breast cancerEileen E Parkes, Kienan I Savage, Tong Lioe, et al.
The Journal of Infectious Diseases|July 19, 2021
Real-World Clinical Outcomes of Bamlanivimab and Casirivimab-Imdevimab Among High-Risk Patients With Mild to Moderate Coronavirus Disease 2019Ravindra Ganesh, Lindsey M Philpot, Dennis M Bierle, et al.
Nature Medicine|January 3, 2025
Sustained virologic suppression of multidrug-resistant HIV in an individual treated with anti-CD4 domain 1 antibody and lenacapavirM Ali Rai, Jana Blazkova, Lela Kardava, et al.
Oncotarget|May 3, 2018
Glucose transporter 1 expression as a marker of prognosis in oesophageal adenocarcinomaJaine K Blayney, Lauren Cairns, Gerald Li, et al.
Pageof 116